Latest Content

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.

The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.

Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.